The OHSU Knight Cancer Institute (Knight) is a matrix cancer center at the Oregon Health &Science University (OHSU) in Portland, Oregon. Founded in 1992 by Grover C. Bagby, Jr. M.D., the Knight has been broadly supported by the university administrative leaders, who have provided space and resources at steadily increasing levels. The Knight Cancer Institute has been supported by the NCI Cancer Center Support Grant since 1997. The OHSU Knight Cancer Institute has 151 members who belong to four scientific programs (Cancer Biology, Hematologic Malignancies, Solid Tumors, and Cancer Prevention and Control). Knight members utilize eight well-established shared resources to perform outstanding research, convert research findings into treatments and preventive agents, and design clinical trials to validate molecular targets. The new Director, Brian Druker, M.D. has sought to refocus the direction of the Knight onto the core values of changing cancer medicine. Institutional investments have added more than 200,000 sq ft in research and clinical space. Sixty-two new members have been added to the Knight, including significant changes in the senior leadership. A gift of $100 million from Phil and Penny Knight (to be given in installments over five to seven years) led to renaming the OHSU Cancer Institute to the OHSU Knight Cancer Institute. Our goal is to invest in people and programs that will advance our mission to make personalized cancer therapy and prevention a reality. As the recognized leader in personalized cancer therapies, our focus has been and will continue to be on investing to make personalized cancer therapy a reality. Investments in people and programs will help us achieve the following goals: 1.) Develop the methodology and capacity to rapidly and comprehensively interrogate individual patient tumors, 2.) Develop the capacity to organize the molecular data into interpretable, pathway focused information, 3.) Develop strategies to understand which pathway alterations are important, 4.) Develop a library of approved and investigational agents that are available to us for human use, 5.) Develop the capacity to rapidly test combinations of therapies targeting multiple genetic abnormalities in cancers, 6.) Develop novel clinical trial designs that will accommodate multi-agent therapies, 7.) Initiate innovative, multi-pathway phase I clinical trials to test our strategy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA069533-15S1
Application #
8530482
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ciolino, Henry P
Project Start
1998-06-22
Project End
2016-06-30
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
15
Fiscal Year
2012
Total Cost
$75,000
Indirect Cost
$18,182
Name
Oregon Health and Science University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
096997515
City
Portland
State
OR
Country
United States
Zip Code
97239
Lane, Ryan S; Femel, Julia; Breazeale, Alec P et al. (2018) IFN?-activated dermal lymphatic vessels inhibit cytotoxic T cells in melanoma and inflamed skin. J Exp Med 215:3057-3074
Smith, Nicholas R; Swain, John R; Davies, Paige S et al. (2018) Monoclonal Antibodies Reveal Dynamic Plasticity Between Lgr5- and Bmi1-Expressing Intestinal Cell Populations. Cell Mol Gastroenterol Hepatol 6:79-96
Langer, E M; Kendsersky, N D; Daniel, C J et al. (2018) ZEB1-repressed microRNAs inhibit autocrine signaling that promotes vascular mimicry of breast cancer cells. Oncogene 37:1005-1019
Sorace, Anna G; Partridge, Savannah C; Li, Xia et al. (2018) Distinguishing benign and malignant breast tumors: preliminary comparison of kinetic modeling approaches using multi-institutional dynamic contrast-enhanced MRI data from the International Breast MR Consortium 6883 trial. J Med Imaging (Bellingham) 5:011019
Medler, Terry R; Murugan, Dhaarini; Horton, Wesley et al. (2018) Complement C5a Fosters Squamous Carcinogenesis and Limits T Cell Response to Chemotherapy. Cancer Cell 34:561-578.e6
Kelley, Katherine A; Wieghard, Nicole; Chin, Yuki et al. (2018) MiR-486-5p Downregulation Marks an Early Event in Colorectal Carcinogenesis. Dis Colon Rectum 61:1290-1296
Davare, Monika A; Henderson, Jacob J; Agarwal, Anupriya et al. (2018) Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma. Clin Cancer Res 24:6471-6482
Kurtz, Stephen E; Eide, Christopher A; Kaempf, Andy et al. (2018) Dual inhibition of JAK1/2 kinases and BCL2: a promising therapeutic strategy for acute myeloid leukemia. Leukemia 32:2025-2028
Sehrawat, Archana; Gao, Lina; Wang, Yuliang et al. (2018) LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. Proc Natl Acad Sci U S A 115:E4179-E4188
Watson, Spencer S; Dane, Mark; Chin, Koei et al. (2018) Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes. Cell Syst 6:329-342.e6

Showing the most recent 10 out of 277 publications